MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$91.83
−7.07%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.53
- Revenue estimate
- $178.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.06
- EPS estimate
- -$0.74
- Revenue actual
- $176.2M
- Revenue estimate
- $166.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -972.2%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $135
- PT range
- $125 – $140
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.74 | -$1.06 | Miss -42.75% | $176.2M |
| May 6, 2026 | -$0.40 | -$13 | Miss -3257.50% | $159.9M |
| Feb 25, 2026 | $0.02 | -$0.11 | Miss -650.00% | $148.9M |
| Aug 6, 2025 | -$0.31 | -$0.12 | Beat 61.29% | $127.8M |
| Feb 26, 2025 | -$0.27 | -$0.49 | Miss -81.48% | $99.4M |
| Feb 28, 2024 | -$0.34 | -$0.66 | Miss -94.12% | $69.6M |
| Nov 2, 2023 | -$0.64 | -$0.57 | Beat 10.94% | $47.7M |
| Aug 3, 2023 | -$0.81 | -$0.92 | Miss -13.58% | $37.5M |
| May 4, 2023 | -$0.96 | -$0.80 | Beat 16.67% | $31.6M |
| Mar 8, 2023 | -$0.98 | -$0.99 | Miss -1.02% | $27.9M |
| Aug 4, 2022 | -$1.05 | -$0.84 | Beat 20.00% | $17.5M |
| May 5, 2022 | -$1.39 | -$1.17 | Beat 15.83% | $12.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026